-
-
-
-
-
-
-
Piper Sandler on Roivant Sciences (ROIV): 'Mosliciguat Ph2 PHocus Takes Center Stage & Catalyst-Rich 2026'
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating and Top Pick on Roivant Sciences (ROIV)
-
-
-
-
-
-
-
Roivant Sciences (ROIV) PT Raised to $38 at Goldman Sachs
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Roivant Sciences (ROIV) Post Investor Day
-
-
-
-
-
-
-
Roivant Sciences (ROIV) files mixed shelf
-
-
-
-
-
-
-
Roivant Sciences (ROIV) PT Raised to $16.50 at BofA Securities
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Roivant Sciences (ROIV)
-
446,711 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

